Department of General Surgery, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University, 85 Wujin Road, Shanghai 200080, China.
Med Oncol. 2012 Sep;29(3):1859-65. doi: 10.1007/s12032-011-0031-9. Epub 2011 Jul 24.
Many recent studies have shown the utility of microRNAs (miRs) as cancer-related biomarkers. The aim of the present study was to evaluate the correlation between miR-203 expression and prognosis of patients with hepatocellular carcinoma (HCC) and cirrhosis after liver transplantation (LT). Sixty-six HCC samples from patients who had undergone LT were examined for miR-203 expression using quantitative reverse transcription-polymerase chain reaction. The data were correlated with clinicopathological parameters and prognosis. Patient survival was analyzed by the Kaplan-Meier method and log-rank test. Cox regression was used for multivariate analysis of prognostic factors. We found that miR-203 expression was low in tumor tissues of patients (n = 16) with post-LT HCC recurrence in comparison with those in patients with non-recurrence (n = 50) (P = 0.003). Patients with higher miR-203 expression had significantly better recurrence-free survival (RFS) and overall survival (OS) (P = 0.016 for RFS; P = 0.014 for OS). Multivariate analysis revealed that high-miR-203 expression was an independent predictor of good prognosis (HR 0.202, P = 0.006 for RFS; HR 0.332, P = 0.013 for OS). Our results suggest that miR-203 could be a novel prognostic marker in HCC patients who have undergone LT and might also be a potential therapeutic target.
许多最近的研究表明,microRNAs(miRs)作为癌症相关生物标志物具有实用性。本研究旨在评估 miR-203 表达与接受肝移植(LT)的肝细胞癌(HCC)和肝硬化患者预后之间的相关性。使用定量逆转录聚合酶链反应检查了 66 例接受 LT 的 HCC 患者的 miR-203 表达。将数据与临床病理参数和预后相关联。使用 Kaplan-Meier 方法和对数秩检验分析患者生存情况。使用 Cox 回归进行预后因素的多变量分析。我们发现,与无复发患者(n=50)相比,LT 后 HCC 复发患者(n=16)的肿瘤组织中 miR-203 表达较低(P=0.003)。miR-203 表达较高的患者具有明显更好的无复发生存(RFS)和总生存(OS)(P=0.016 用于 RFS;P=0.014 用于 OS)。多变量分析显示,高 miR-203 表达是良好预后的独立预测因子(RFS 的 HR 为 0.202,P=0.006;OS 的 HR 为 0.332,P=0.013)。我们的结果表明,miR-203 可能是接受 LT 的 HCC 患者的一种新的预后标志物,也可能是潜在的治疗靶点。